BJMO - volume 13, issue 5, august 2019
T. Feys MBA, MSc, P. Vuylsteke MD
The highlights in gynecologic cancers from ASCO 2019 include data on the outcome of chemotherapy or PARP inhibitors as monotherapy or combination therapy in (elderly) patients with ovarian cancer, as well as results of immune checkpoint blockade in patients with advanced or recurrent endometrial cancer with or without a mismatch repair deficiency. Novel findings in (early-stage) cervical cancer include the efficacy and safety of neoadjuvant chemotherapy followed by surgery vs. chemoradiation, and of minimally invasive hysterectomy compared to open radical hysterectomy.
Read moreBJMO - volume 12, issue 1, february 2018
D. Verhoeven MD, PhD, F.P. Duhoux MD, PhD, E. de Azambuja MD, PhD, H. Wildiers MD, PhD, P. Vuylsteke MD, A. Barbeaux MD, N. van Damme , E. Van Eycken MD
Limited literature is available about quality management in systemic treatment of breast cancer patients. Professionals are the key players in the identification and interpretation of quality indicators. The Belgian Society of Medical Oncology takes the lead in the field of quality management of systemic treatment for cancer, especially breast cancer. A narrow collaboration with the Belgian Cancer Registry will allow benchmarking. The results will be presented and discussed between peers of the society. This should lead to better outcomes for all Belgian centres. All Belgian Society of Medical Oncology members are called for active participation
(BELG J MED ONCOL 2018;12(1):15–21)
Read moreBJMO - 2017, issue 3, february 2017
L. Jongen , P. Neven MD, PhD, A. Lintermans , K. Van Asten MSc, C. Blomme , D. Lambrechts PhD, A. Poppe , H. Wildiers MD, PhD, A.S. Dieudonné , J. Decloedt , P. Berteloot , D. Verhoeven MD, PhD, M. Joerger , P. Vuylsteke MD, W. Wyendaele , M. Casteels , S. Van Huffel , W. Lybaert MD, J. Van Ginderachter , R. Paridaens , I. Vergote , V. Dezentjé , B. Van Calster PhD, H-J. Guchelaar
BJMO - volume 11, issue 1, february 2017
P. Vuylsteke MD, J.C. Goeminne MD, S. Henry MD, V. Vanhaudenarde MD, B. Willemart MD, P. Marchettini MD, D. Taylor MD
Tumour infiltrating lymphocytes are a sign of immune mediated reaction of the host against the tumour. They are considered as a positive prognostic marker and may also have a predictive role for the use of certain therapies. The challenge remains to convert tumours with low tumour infiltrating lymphocytes into tumours with high tumour infiltrating lymphocytes in order to enhance the immune mediated effect of therapies.
PIK3Ca mutation is one of the most frequent mutations encountered in breast cancer, particularly in hormone receptor positive cancer in which it can confer resistance to hormonal therapy. Therefore, a lot of effort has been made to target the PI3K-pathway with drugs, and to find a way to predict their efficacy: some results have been achieved; in particular with the detection of PIK3Ca in circulating DNA, but many questions still remain. This article provides an overview concerning these two biomarkers, and attempts to determine whether they could be used in clinical practice today.
(BELG J MED ONCOL 2017;11(1):7–11)
Read moreBJMO - volume 6, issue 1, february 2012
J. De Grève MD, PhD, L. Dirix MD, PhD, P. Vuylsteke MD, H. Wildiers MD, PhD
2011 has been a rich year in progress on cancer care. Items already mentioned last year have been confirmed in full papers and are entering daily clinical practice. This article summarises the highlights in oncology of the past year.
(BELG J MED ONCOL 2012;6:38–41)
Read moreBJMO - volume 6, issue 1, february 2012
J. De Grève MD, PhD, L. Dirix MD, PhD, P. Vuylsteke MD, H. Wildiers MD, PhD
2011 has been a rich year in progress on cancer care. Items already mentioned last year have been confirmed in full papers and are entering daily clinical practice. This article summarises the highlights in oncology of the past year.
(BELG J MED ONCOL 2012;6:38–41)
Read more
Top
